Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure

AIMS: Heart failure (HF) is associated with considerable symptom burden and impairment in physical functioning and quality of life. The sodium–glucose co‐transporter 2 inhibitor empagliflozin reduced the risk of HF hospitalisation and cardiovascular death in patients with type 2 diabetes and establi...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, William T., Ponikowski, Piotr, Brueckmann, Martina, Zeller, Cordula, Macesic, Hemani, Peil, Barbara, Brun, Michèle, Ustyugova, Anastasia, Jamal, Waheed, Salsali, Afshin, Lindenfeld, JoAnn, Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2019
Materias:
Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774309/
https://www.ncbi.nlm.nih.gov/pubmed/31218819
http://dx.doi.org/10.1002/ejhf.1486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774309/
https://www.ncbi.nlm.nih.gov/pubmed/31218819
http://dx.doi.org/10.1002/ejhf.1486

Ejemplares similares